We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+61.09%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$96M
AUM Growth
-$68.2M
(-42%)
Cap. Flow
-$86.6M
Cap. Flow
% of AUM
-90.21%
Top 10 Holdings %
Top 10 Hldgs %
77.1%
Holding
33
New
9
Increased
–
Reduced
8
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$7.64M |
| 2 |
IVA
Inventiva
IVA
|
+$6.97M |
| 3 |
Minerva Neurosciences
NERV
|
+$6.15M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$3.91M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$3.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$15M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$10.2M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
+$8.17M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$7.37M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DFTX
26
Definium Therapeutics
DFTX
$5.73B
| – | – |
-361,444
| Closed | -$4.26M |
|
27
Monopar Therapeutics
MNPR
$736M
| – | – |
-64,455
| Closed | -$5.26M |
|
|
28
CALL
Praxis Precision Medicines
PRAX
$9.07B
| – | – |
-100,000
| Closed | -$5.3M |
|
|
SLNO
29
CALL
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-250,000
| Closed | -$16.9M |
|
30
Tarsus Pharmaceuticals
TARS
$2.56B
| – | – |
-70,778
| Closed | -$4.21M |
|
|
LENZ
31
LENZ Therapeutics
LENZ
$172M
| – | – |
-175,363
| Closed | -$8.17M |
|
|
ATYR
32
CALL
aTyr Pharma
ATYR
$46.4M
| – | – |
-600,000
| Closed | -$433K |
|
|
TECX
33
Tectonic Therapeutic
TECX
$573M
| – | – |
-138,595
| Closed | -$2.17M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2025 Portfolio in Review
As of Q4 2025, Ally Bridge Group held 33 positions worth $96M, down 42% from $164M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Ally Bridge Group withdrew a net $86.6M in Q4 2025, closing 15 positions and reducing 8 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $15M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 73% a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in Abivax worth $9.44M.
- Ally Bridge Group's largest Q4 2025 buy was Abivax: 70,000 shares worth $9.44M.
- Ally Bridge Group's biggest Q4 2025 reduction was Soleno Therapeutics, cutting an estimated $7.37M.
- Ally Bridge Group fully exited Madrigal Pharmaceuticals in Q4 2025, selling an estimated $15M.
- Ally Bridge Group's ten largest holdings make up 77% of its $96M portfolio in Q4 2025.
- Ally Bridge Group opened 9 new positions and closed 15 in Q4 2025.
- Ally Bridge Group's portfolio value fell 42% quarter-over-quarter to $96M.
Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.